Answers from the Lab

(00:32)

Dr. Dubey, could you just tell the audience a little bit about yourself and your background?

(01:56)
 No one knows (better) what tests are necessary for these auto-immune patients than our lab directors who are doing really both things, seeing patients and working in the lab, so I think that's a really unique thing we want to highlight, right?

(03:11)
 Can you maybe describe a little bit about that process? Because I think it will help our audience understand what that really means. The integration between the clinic, the research lab and the clinical lab.

(05:54)
 Dr. Dubey, can you just elaborate a little bit more on our methodology and the assay that will be used for this important test?

(06:55)
 And it sounds like this test is just another example of that, where it's something that not everyone can do, but because of our expertise that we're able to provide a test that is as accurate and yet handles the high throughput that Mayo clinic receives?

(07:57)

Is unique in that Mayo clinic will be the first ones offering this commercially, right?

(08:25)

So can you help physicians understand which kind of patients would be the right candidates for this type of thing?

(09:50)

Do you have any recommendations for other testing that should be done for these patients to rule in or out a specific disease?

(11:14)

Is there any reason that there'd be genetic tests or any other laboratory tests ordered before kelch 11, or are we really just looking for those males with rapid onset attacks, SIA, those, uh, presentation symptoms you described earlier?

(13:12)

We don't want to delay very long before we order this Kelch-11 antibody tests or any of the other antibodies, right?

(14:49)

Will it eventually be added into the movement disorder and the encephalopathy and maybe the other phenotypes specifically?

(15:27)

For the time being physicians will have to order it in addition to the panels, but then eventually it will be included in our comprehensive evaluation?

(15:37)

When those results come back positive, how is this going to impact patient care, prognosis, and treatment plans for the patient?

(17:14)

Are you saying Dr. Dubey, that this is probably going to be as prevalent as some of those Hu, Ri, and Yo antibodies that physicians have known about for you?

(17:50)

Dr. Dubey, is there anything else that you want to leave our physicians with that you're most excited about with this test?

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and

Bobbi Pritt, M.D. review where the pandemic stands now, and discuss concerns that continue to linger regarding COVID-19 and other respiratory illnesses. 

(00:31):

But before we get started, Dr. Pritt, could you provide our listeners with a little bit about you and your background?

(01:22):

Can you provide a brief overview and intended use of this testing?

(03:16):

Could you describe what clinical action is enabled by the results of this test?

(05:31):

Now let's discuss which patients should have this testing and when should it be performed?’

(06:56):

Can you now explain, how does this test improve upon previous testing approaches?

(08:04):

Are there other options on the market? If so, what makes our testing different or unique?

(00:31):

Before we get started, Dr. Halling, could you provide us with a little bit about you and your background?

(01:11):

Would you like to give us a basic summary of this test?

(02:43):

So in talking about patients, can you tell us which patients should have this testing? And when it is typically performed?

(05:01):

Do you want to talk about some of the guidelines that were used to shape the genes included in this panel?

(05:36):

Can you tell us a bit about the alternative test options that are available and how they compare to this large panel?

(06:42):

So I know most other panels on the market assess for mutations and fusions. Is there a reason why our panel also looks at amplifications and are certain subset of the genes?

(07:29):

So do you want to talk about how this panel offers some benefits over other large panels in the market?

(08:46):

Let's talk a little bit about how the results of this test can be used in patient care.

(00:32):

Before we get started, I'm really interested, could you give me a little bit of background on yourself and, uh, just where you work at Mayo Clinic?

(01:31):

So before we start talking about the tests, can you just tell me a little bit about TMA and in that disease state itself?

(03:08):

As we talk very specifically about this testing, so can you give me a brief overview of the assays we're using here at Mayo clinic to diagnose this disease state?

(05:12):

So this testing is really comprehensive and that it covers what you said, classic and alternative, correct? And that it's kind of making sure that anything that's outside of the norm, we're picking up in that one comprehensive test so you're not having to kind of pick through bits and pieces with a bunch of single individual tests. Am I correct and understand kind of how you brought that up?

(08:39):

As you get those results back, how does that affect how you treat a patient? What are the treatments for them as, as you go through this, once you've made that decision?

(09:35):

So there's a lot of movement in this space that is really probably driving the need for a lot of understanding this complement testing and seeing that full clinical picture, because you have to know you now have different therapies to choose from?